ClinicalTrials.gg
CompletedNCT03778047Updated Nov 3, 2020

A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

A Phase 1 interventional study of Enzalutamide and HC1119 in Metastatic Castration Resistant Prostate Cancer, sponsored by Hinova Pharmaceuticals Inc.. Completed at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-03.

Sponsored by Hinova Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Feb 2018, registered Dec 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
111th of 125
10 · median 52
Started
2018
with 3 others
Phase 1
22 of 125
2 open now
Registered
87th of 125
by date
Lead sponsor
3 of 125
Hinova Pharmaceuticals Inc.

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 111th largest by enrollment, is one of 4 that started in 2018, is one of 22 in phase 1, and was the 87th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a study for evaluating enzalutamide pharmacokinetics and pharmacodynamics, and related changes after drug switch in Chinese patients with metastatic castration-resistant prostate cancer. The study primary objective is to evaluate the pharmacokinetic characteristics of enzalutamide in Chinese patients with mCRPC.

03

Conditions studied

  • Metastatic Castration Resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participated in the study, with understanding of and will to comply with relevant study procedures and signed form;
  2. Chinese male, ≥ 18 years old;
  3. With or cytologically confirmed prostate cancer, without neuroendocrine carcinoma or ductal adenocarcinoma;
  4. With evidence of lesions (such as bone scan and CT/MRI);
  5. Patients with , refractory, or progressive disease despite castration (surgery or chemical) or combined androgen deprivation therapy. (Progressive disease is defined as 1 or more of the following 3 criteria: PSA progression: A minimum of 3 rising PSA values with an interval of at least 1 week between determinations, resulting in a final value higher than 50% of the minimum, with a starting PSA value > 2 ng/ml; Soft tissue disease progression as defined by 1.1; Bone progression as defined by PCWG2 with 2 or more new lesions on bone scan);
  6. Castrate levels of testosterone (\< 50 ng/dl) at screening; bilateral orchiectomy or ongoing androgen deprivation therapy with effective GnRH analogues;
  7. performance status ≤1;
  8. Laboratory tests must meet the following criteria:

    1. Routine Blood Test: (Hb) ≥ 90g/L (no blood transfusions within 14 days prior to screening); (ANC) ≥ 1.5 x 109/L; Count (PLT) ≥ 80 x 109/L;
    2. Blood Biochemistry: creatinine (Cr) ≤ 2 x (ULN), or Cr > 2 x ULN but the calculated ≥ 60 ml/min; (BIL) ≤2 x ULN; (ALT), aspartate aminotransferase (AST) ≤2.5 x ULN (or ≤ 5.0 x ULN for patients with liver metastases);
    3. Coagulation: \< 1.5.
  9. Estimated > 6 months.

Exclusion criteria

Exclusion Criteria:

  1. Participated in other clinical drug trials within 1 month prior to screening, or the occurrence of toxicity caused by previous treatments that has not been relieved to ≤ Grade 2 toxicity (according to 4.03) prior to enrollment;
  2. ;
  3. Subjects are excluded if any of the following conditions are met:

    1. Other within the last 5 years (except for curatively treated non-melanoma skin cancer);
    2. History of organ transplants;
    3. Past medical history of seizures, serious CNS diseases, or unexplained coma, family history of seizures, or history of traumatic brain injury;
    4. Uncontrolled hypertension (systolic ≥ 160 mmHg or diastolic ≥ 100 mmHg) or other serious cardiovascular diseases. (Patients with a history of hypertension is eligible if his blood pressure is controlled with antihypertensives);
    5. Significant GI dysfunction which may affect the intake, transport, or absorption of drug (such as inability to swallow, chronic diarrhea, and bowel obstruction, etc.), or patients with complete gastrectomy;
    6. Other uncontrolled clinical diseases, including but not limited to: persistent or active infections.
  4. Subjects are excluded if any of the following conditions regarding past or concomitant medication are met:

    1. Medications that lower the seizure threshold must be used during the trial;
    2. Treatment with 5α-reductase inhibitors (finasteride, dutasteride), estrogen, or cyproterone within 4 weeks prior to screening;
    3. Treatment with ketoconazole within 4 weeks prior to screening;
    4. Previously treated with or approved medications that inhibit testosterone synthesis (such as abiraterone acetate, TAK-683, and TAK-448) or target testosterone receptors (such as SHR3680, proxalutamide, and ARN509), except for bicalutamide and flutamide.
  5. Known to any ingredient of the study drugs (enzalutamide and HC-1119) or similar drugs;
  6. seropositive;
  7. History of medication or drug abuse;
  8. Other conditions that subject is determined by the investigator to be unsuitable for this study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    enzalutamide

    160mg

    Drug: Enzalutamide

  • Experimental
    HC-1119

    To be determined

    Drug: HC1119

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum drug concentration(Cmax)

    Time frame: From the first dose of the study drug to 12 weeks after dose

  2. Time of maximum drug concentration(Tmax)

    Time frame: From the first dose of the study drug to 12 weeks after dose

  3. Area under curve from time 0 to 24h (AUC0-24h)

    Time frame: From the first dose of the study drug to 12 weeks after dose

Secondary outcomes

  1. Maximum drug concentration(Cmax)

    Time frame: From 13 weeks to 24 weeks after dose

  2. Time of maximum drug concentration(Tmax)

    Time frame: From 13 weeks to 24 weeks after dose

  3. Area under curve from time 0 to 24h (AUC0-24h)

    Time frame: From 13 weeks to 24 weeks after dose

  4. Number of patients with adverse events

    Safety measures

    Time frame: From the first dose of the study drug to 24 weeks after dose

  5. Percentage of patients with > 50% decrease in prostate specific antigen (PSA)

    Percentage of patients with \> 50% decrease in PSA levels from baseline at weeks1,3,5 6, 8, 10, and 12.

    Time frame: From the first dose of the study drug to 12 weeks after dose

07

Study locations

1 site
  • Medical Ethics Committee of Hunan Cancer Hospital
    Changsha, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Oct 2018, 8 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 8 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2018
First posted
Dec 19, 2018
StartActual
Feb 7, 2018
Primary completionActual
Oct 24, 2018
CompletionActual
Aug 28, 2019
Last update
Nov 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03778047
Lead sponsor
Hinova Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Dec 19, 2018
Start date
Feb 7, 2018
Primary completion
Oct 24, 2018
Completion
Aug 28, 2019
Last update
Nov 3, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion